Immuno-Oncology Resource Center

Immuno-Oncology Resource Center

September 05, 2019
1 min read

Samuel Waxman Cancer Research Foundation awards $1.4 million in grants

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Samuel Waxman
Samuel Waxman

The Samuel Waxman Cancer Research Foundation awarded $1.4 million worth of new grants to fund investigations into multiple scientific areas.

The grants — which will fund research from 2019 through 2021 in areas such as aging and cancer, abnormal gene expression, differentiation therapy and epigenetic therapy — bring to more than $2 million the amount of donor-supported funding the foundation has awarded for cancer research this year.

The foundation now funds 50 physician-scientists as part of its Institute Without Walls initiative, intended to promote collaboration and break down institutional silos.

“The [foundation] is making a substantial investment in funding cutting-edge research ideas that show remarkable promise for uncovering abnormal gene expression in cancer and developing less toxic therapies,” Samuel Waxman, MD, founder and CEO of the foundation, said in a press release. “ We welcome these scientists to the [foundation’s] Institute Without Walls, which will expand our network of scientists committed to cross-disciplinary and cross-institutional collaboration as a mechanism to hasten discoveries . ”

The grant recipients and their research focus areas are:

  • Tyler J. Curiel, MD, MPH, of The University of Texas Health Science Center at San Antonio — Age effects of T cell stem cells, cancer stem cells and immune checkpoints on cancer immunotherapy;
  • Ronald M. Evans, PhD, of The Salk Institute for Biological Studies — FXR as a novel therapeutic target in colitis-induced colorectal cancer;
  • Maria E. Figueroa, MD, of University of Miami — The role of age-related reprogramming of KLF6 in HSC dysfunction and myeloid malignancies;
  • Jan Karlseder, PhD, of The Salk Institute for Biological Studies — The regulation of proliferative boundaries by autophagy;
  • Ross Levine, MD, of Memorial Sloan Kettering Cancer Center — Determining the role of somatic clonal evolution in aging, hematopoiesis and predisposition to malignancies;
  • Joel Neilson, PhD, of Baylor College of Medicine — In vivo disruption of a novel translation pre-initiation complex as a putative therapeutic vulnerability for breast cancer differentiation therapy; and
  • Emmanuelle Passegue, PhD, of Columbia University — Autophagy and hematopoietic stem cell function in aging and leukemia.

The nonprofit Samuel Waxman Cancer Research Foundation funds cutting-edge research that identifies and corrects abnormal gene function that causes cancer. Since its inception in 1976, the foundation has awarded approximately $100 million to support the work of more than 200 researchers worldwide.